25.JPG)
The Phage Therapy Market is expected to grow at an 18.29 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The increasing number of people living with infectious illnesses is expected to fuel the growth of this market. If bacterial infections rose, the demand for phase therapy would skyrocket.
- The phage therapy industry is expected to grow steadily, driven by increased patient numbers and increasing concerns about antibiotics.
- North America dominated the market and accounted for a global revenue share in 2023.
- A severe lack of qualified healthcare workers and a lack of knowledge hinders the implementation of phage therapy methods.
Phage therapy industry is experiencing huge research and development activities to develop products for different diseases and applications.The global phage therapy market is under development with no FDA-approved products. In the current scenario, natural phage-based products and compassionate phage therapy (CPT) are available in the market, which comprises current market revenue. Players such as Microgen (Russia), Duopharm (Germany), SES DERMA (Peru), BIOMED PERM NPO (Russia), and Phage Therapy Center are offering treatment for patients with chronic infectious diseases. However, the global phage therapy market has a tremendous opportunity to grow during the forecast period. By region, Europe dominates the market with a share of 57.0% of the global phage therapy market. Russia and Germany are the key markets holding the majority of the market for phage therapy in the region.
The market has reputed players across the globe with massive investment in clinical trials/ R&D activities. Clinical trial/product development companies in the market form strategic alliances with key pharmaceutical vendors to seek investment and tap potential markets in upcoming forecast years. Strategic alliances with contract manufacturers, the scientific community, and policymakers will enhance the development of phage therapy for clinical trials companies. The rapid increase in investment in the phage industry has been seen in recent years due to significant market opportunities in upcoming years.
Competitive Landscape
Some of The Key Players in the Phage Therapy Market:
- Armata Pharmaceuticals, Inc.,
- Adaptive Phage Therapeutics,
- AmpliPhi Biosciences,
- BiomX (MBcure Ltd.),
- C3J Therapeutics,
- Enbiotix,
- Eligo Bioscience,
- Intralytix, Inc.,
- InnoPhage,
- iNtODEWorld,
- Locus Biosciences,
- MicroPhage, Inc.,
- Phage International,
- PhagoMed Biopharma GmbH,
- Pherecydes Pharma SA,
- TechnoPhage,
- Phagelux,
- SNIPR BIOME,
- Microgen Russia
Market Segmentation
The global phage therapy market is segmented on the basis of Therapeutic Area , Route of Administration, and region. Based on the Therapeutic Area , the market is divided into Infectious Diseases, Oncological Disorders, and Other Disorders. On the basis of Route of Administration, the market is segmented into Oral, Topical, Rectal, and Intravenous. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and the Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
Recent Developments:
- In March 2024, BiomX Inc. and Adaptive Phage Therapeutics, Inc. announced they had entered into a definitive merger agreement. BiomX is a clinical-stage company that studies and develops natural and engineered phage therapies that target specific pathogenic bacteria.
- In January 2024, Technophage, a biopharmaceutical business that focuses on developing and producing biologics, namely those derived from bacteriophages, officially announced the successful dosing of the first patient in this critical stage. This clinical trial (ID: NCT05948592) is to determine if TP-102 is effective in treating diabetic foot ulcers caused by Staphylococcus aureus, Pseudomonas, and Acinetobacter baumannii.
The Phage Therapy Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 18.29 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Therapeutic Area, By Route of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Armata Pharmaceuticals, Inc., Adaptive Phage Therapeutics, AmpliPhi Biosciences, BiomX (MBcure Ltd.), C3J Therapeutics, Enbiotix, Eligo Bioscience, Intralytix, Inc., InnoPhage, iNtODEWorld, Locus Biosciences, MicroPhage, Inc., Phage International, PhagoMed Biopharma GmbH, Pherecydes Pharma SA, TechnoPhage, Phagelux, SNIPR BIOME, and Microgen Russia |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
